- Home
- HGTY vs GYRE Comparison
HGTY vs GYRE Comparison
Compare HGTY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- GYRE
- Stock Information
- Founded
- HGTY 1984
- GYRE 2002
- Country
- HGTY United States
- GYRE United States
- Employees
- HGTY N/A
- GYRE N/A
- Industry
- HGTY Specialty Insurers
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HGTY Finance
- GYRE Health Care
- Exchange
- HGTY Nasdaq
- GYRE Nasdaq
- Market Cap
- HGTY 995.8M
- GYRE 1.1B
- IPO Year
- HGTY N/A
- GYRE N/A
- Fundamental
- Price
- HGTY $9.54
- GYRE $10.52
- Analyst Decision
- HGTY Hold
- GYRE
- Analyst Count
- HGTY 3
- GYRE 0
- Target Price
- HGTY $11.00
- GYRE N/A
- AVG Volume (30 Days)
- HGTY 65.1K
- GYRE 132.7K
- Earning Date
- HGTY 11-07-2024
- GYRE 11-13-2024
- Dividend Yield
- HGTY N/A
- GYRE N/A
- EPS Growth
- HGTY N/A
- GYRE N/A
- EPS
- HGTY 0.11
- GYRE N/A
- Revenue
- HGTY $1,153,350,000.00
- GYRE $105,033,000.00
- Revenue This Year
- HGTY $21.17
- GYRE $25.32
- Revenue Next Year
- HGTY $14.52
- GYRE $12.95
- P/E Ratio
- HGTY $89.70
- GYRE N/A
- Revenue Growth
- HGTY 21.13
- GYRE N/A
- 52 Week Low
- HGTY $7.68
- GYRE $8.26
- 52 Week High
- HGTY $12.35
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- HGTY 33.65
- GYRE 45.59
- Support Level
- HGTY $9.16
- GYRE $9.51
- Resistance Level
- HGTY $9.96
- GYRE $10.58
- Average True Range (ATR)
- HGTY 0.25
- GYRE 0.95
- MACD
- HGTY -0.03
- GYRE -0.10
- Stochastic Oscillator
- HGTY 29.17
- GYRE 20.57
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.